RxDoctor Payments Data

Aleksandra Rachitskaya, MD

Retina Specialist · Cleveland, OHNPI 1487802757

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $205,439 of the $303,177 with a category attached, or 67.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 17.5%. Among retina specialist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$303,177in general payments, 2019–2025

Across 211 payments — averaging $1436.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$53K
  • Apellis Pharmaceuticals, Inc.$48K
  • Boehringer Ingelheim International GmbH$35K
  • Regeneron Healthcare Solutions, Inc.$22K
  • Alcon Research LLC$20K
  • Novartis$19K
  • plus $106K from 15 others
$1,846,221in research payments, 2019–2025

Across 120 payments — averaging $15,385 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Apellis Pharmaceuticals, Inc.$886K
  • Genentech, Inc.$740K
  • Novartis$168K
  • Cortigent Inc$27K
  • F. Hoffmann-la Roche AG$16K
  • Regeneron$11K

What the payments were for

  • Consulting fees$205,43968%
  • Speaking & faculty fees$63,24221%
  • Travel & lodging$27,0309%
  • Food & beverage$6,8472%
  • Education$6190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$303,177 in reported general payments places this provider in the 95th percentile of 69 retina specialist providers in Ohio.

See all retina specialist providers in Ohio

Medicare billing

Part B allowed, 2024
$241,611
Medicare patients
747
Services billed
4,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Difluprednate36$3,963
Prednisolone Acetate108$3,636
Brinzolamide13$1,825
Latanoprost49$1,002
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat48$706
Atropine Sulfate23$576
Ketorolac Tromethamine30$471
Ciprofloxacin Hcl37$361
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$227
Brimonidine Tartrate21$103

Paid to pharmacies, not to this prescriber.

Other retina specialist in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →